These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25775634)

  • 21. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses.
    Zeichner JA; Stern DW; Uliasz A; Itenberg S; Lebwohl M
    J Am Acad Dermatol; 2009 Jan; 60(1):59-62. PubMed ID: 18937999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of imiquimod cream 5% in the treatment of localized morphea.
    Man J; Dytoc MT
    J Cutan Med Surg; 2004; 8(3):166-9. PubMed ID: 15129316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
    Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imiquimod in clinical practice.
    Edwards L
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S14-6. PubMed ID: 9842096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial.
    Kumar P; Dar L; Saldiwal S; Varma S; Datt Upadhyay A; Talwar D; Sharma VK; Verma KK; Dwivedi SN; Raj R; Gupta S
    JAMA Dermatol; 2014 Oct; 150(10):1072-8. PubMed ID: 25103148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial.
    Chen K; Yap LM; Marks R; Shumack S
    Australas J Dermatol; 2003 Nov; 44(4):250-5. PubMed ID: 14616490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study.
    Kroft EB; Groeneveld TJ; Seyger MM; de Jong EM
    Am J Clin Dermatol; 2009; 10(3):181-7. PubMed ID: 19354332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical calcipotriene for morphea/linear scleroderma.
    Cunningham BB; Landells ID; Langman C; Sailer DE; Paller AS
    J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):211-5. PubMed ID: 9704831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li C; Zhu HS; Li P; Li C; Chan TC; Cheng VC; Chan KH; Yuen KY
    Clin Infect Dis; 2014 Nov; 59(9):1246-55. PubMed ID: 25048848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imiquimod in the treatment of cutaneous warts: an evidence-based review.
    Ahn CS; Huang WW
    Am J Clin Dermatol; 2014 Oct; 15(5):387-99. PubMed ID: 25186654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology.
    Szeimies RM; Gerritsen MJ; Gupta G; Ortonne JP; Serresi S; Bichel J; Lee JH; Fox TL; Alomar A
    J Am Acad Dermatol; 2004 Oct; 51(4):547-55. PubMed ID: 15389189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
    Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
    J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.
    Seeberger J; Daoud S; Pammer J
    Int J Dermatol; 2003 Jul; 42(7):576-9. PubMed ID: 12839616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.
    Harrison LI; Skinner SL; Marbury TC; Owens ML; Kurup S; McKane S; Greene RJ
    Arch Dermatol Res; 2004 Jun; 296(1):6-11. PubMed ID: 15083310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
    Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
    J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
    Strohal R; Kerl H; Schuster L
    J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus.
    Cutler K; Kagen MH; Don PC; McAleer P; Weinberg JM
    Acta Derm Venereol; 2000; 80(2):134-5. PubMed ID: 10877136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.